文献速递类风湿关节炎

提升患者对药物风险与获益的理解:DrugFactsBox与SMART推理训练研究

Enhancing Patient Understanding of Medication Risks and Benefits.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-12-22

该研究采用2×2析因设计,将286例类风湿关节炎患者随机分配至DrugFactsBox或常规药物信息联合SMART推理训练或不联合的四组,评估知情决策。结果显示两种干预均无主效应,但SMART组在基线未达知情决策标准者中6个月达标率42.5%,高于无SMART组的23.6%(均差18.9,95%CI 5.6-32.2,P=0.007),差异源于知识提升。

要点

  • DrugFactsBox与SMART训练单独或联合均无主效应。
  • 基线未达知情决策标准者中,SMART组6个月达标率42.5%高于无SMART组23.6%(P=0.007)。
  • 差异由SMART组知识增加驱动,基线已达标者两组无显著差异。

核心结论

  • 参与旨在提升要义推理的理论驱动项目可能对治疗选择知识不足的类风湿关节炎患者的知情决策有益。

研究设计与样本

  • 采用2×2析因研究设计,共286例类风湿关节炎患者随机分配至DrugFactsBox联合SMART、DrugFactsBox不联合SMART、其他消费者药物信息联合SMART、其他消费者药物信息不联合SMART四组。
  • 通过电话访谈和在线问卷在基线及基线后6周、3个月、6个月共4个时间点收集数据。
  • 主要结局变量为知情决策,定义为基于充分知识做出关于使用改善病情抗风湿药的价值一致性决策。

主要发现

  • 两种干预单独或联合均未发现主效应。
  • SMART/无SMART分组与基线知情决策之间存在显著交互作用。
  • 基线未达知情决策标准的SMART组参与者中42.5%在6个月随访时达标,无SMART组为23.6%(均差18.9,95%CI 5.6-32.2,P=0.007)。
  • 该差异由SMART组知识增加驱动。
  • 基线已符合知情决策标准者中,SMART组与无SMART组差异无统计学意义。

关键数值与推荐

  • 知情决策定义为基于充分知识做出关于使用改善病情抗风湿药的价值一致性决策。
  • 基线未达知情决策标准者6个月达标率:SMART组42.5% vs 无SMART组23.6%,均差18.9(95%CI 5.6-32.2),P=0.007。

临床怎么用

  • 对于治疗选择知识不足的类风湿关节炎患者,可考虑采用提升要义推理能力的理论驱动项目以促进知情决策。
  • DrugFactsBox格式或SMART训练单独使用未见主效应,联合使用亦未显示额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of 2 interventions, including the DrugFactsBox format for presenting written medication information and the SMART (Strategic Memory Advanced Reasoning Training) program designed to enhance gist (i.e., "bottom-line" meaning) reasoning ability. METHODS: We used a 2 × 2 factorial research design. A total of 286 patients with rheumatoid arthritis were randomly assigned to 1 of 4 groups, including DrugFactsBox with the SMART program, DrugFactsBox without the SMART program, other consumer medication information (CMI) with the SMART program, and other CMI without the SMART program. Data were collected via telephone interviews and online questionnaires at 4 time points, including baseline and 6-week, 3-month, and 6-month time points following baseline. The primary outcome variable was informed decision-making, which was defined as making a value-consistent decision concerning use of disease-modifying antirheumatic drugs based on adequate knowledge. RESULTS: We found no main effects for the 2 interventions, either alone or in combination. However, there was a significant interaction between assignment to the SMART/no SMART groups and informed decision-making at baseline. Among participants in the SMART groups who did not meet the criteria for informed decision-making at baseline, 42.5% met the criteria at the 6-month follow-up, compared to 23.6% of participants in the no SMART groups (mean difference 18.9 [95% confidence interval 5.6, 32.2]; P = 0.007). This difference was driven by increased knowledge in the SMART groups. Among participants who met the criteria for informed decision-making at baseline, the difference between the SMART and no SMART groups was not statistically significant. CONCLUSION: Participation in a theory-driven program to enhance gist reasoning may have a beneficial effect on informed decision-making among patients with inadequate knowledge concerning therapeutic options.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Blalock SJ, Solow EB, Reyna VF, et al. Enhancing Patient Understanding of Medication Risks and Benefits. Arthritis Care Res (Hoboken). 2021. PMID: 32799397. doi:10.1002/acr.24421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。